Good piece on biosimilars in Forbes by Jon Entine, Senior Fellow at the Center for Health & Risk Communication at George Mason University. Read FDA Balances Costs, Patient Safety in the Biologics and Personalized Medicine
Media Room
Forbes: FDA Balances Costs, Patient Safety in the Biologics and Personalized Medicine
Monday, July 23rd, 2012